Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Short Interest Update
by Jessica Moore · The Cerbat GemRocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Get Free Report) was the target of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 7,772 shares, a growth of 362.9% from the February 26th total of 1,679 shares. Based on an average daily trading volume, of 8,985 shares, the short-interest ratio is presently 0.9 days.
Rocket Pharmaceuticals Trading Down 9.4%
Shares of Rocket Pharmaceuticals stock opened at $0.02 on Friday. The stock has a 50 day moving average of $0.02 and a 200 day moving average of $0.03. Rocket Pharmaceuticals has a fifty-two week low of $0.01 and a fifty-two week high of $0.09.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.
Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.